Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/22/2020 9:58:20 AM - Followers: 196 - Board type: Free - Posts Today: 2

Trading for
$0.061 as of Thurs. March 29th, 2018, well under two recent Price Targets of $2.00 and $0.50.
Increased chatter amongst investors of a Partnership or Buyout, see below. 

Latest Analyst Ratings:

March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.

March 29th, 2018 
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.

Latest Earnings Report - March 28th, 2018
EPS of $-0.28 misses by $-0.02 
Revenue of $5.39M (- 43.3% Y/Y) beats by $1.29M

Trader's takeaway from the latest Earnings Report: (Updated on April 1st, 2018)
1. No R/S mentioned, 2. Tiara Prescreen implementation in Europe soon (as early as this week), 3. Updates on Tiara / Reducer enrollments shown to have been very successful and increasing in size, 4. Cash to last through Q3 2018, 5. Revenues were down/but so were expenses.

Also on the conference call, they reported that the $112 M lawsuit has been fully paid and settled. Neovasc said that “there are no other monetary damages arising from the award,” and announced that it will remain the joint inventor of its ‘964 patent related to its Tiara transcatheter mitral valve replacement device. Neovasc will share the patent along with 2 employees of CardiAQ Valve, with both parties “having freedom to use the patent without an obligation to pay royalties to the other", according to a press release. Source: NeoVasc shares surge 45% on affirmed Tiara patent case decision against Edwards.  https://www.massdevice.com/neovasc-shares-surge-45-affirmed-tiara-patent-case-decision-edwards/

Possible Partnership in the works?
This was taken from the latest Earnings Conference call on March 28th, 2018 (link to entire transcript provided above, courtesy of SeekingAlpha.com)
Newly acquired CEO/President Fred Colen hints at being open to a partnership.  Have a look at what he says:
Possible partnership?

Possible Buy Out in the works? 
Check out newly acquired CEO Fred Colen's bio below (spoiler alert: he worked with $BSX for 8 years as CTO) and see how this all ties together. 

Don't Be Surprised if Boston Scientific (BSX) Buys Neovasc (NVCN)- JMP  

MARCH 30, 2018 Article:

Neovasc has a unique opportunity to take a share of that US$16.2 Billion with this patent along with many other patents that they own.
Patent # 
SOURCE:  http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,579,964.PN.&OS=PN/8,579,964&RS=PN/8,579,964

Neovasc's Tiara and other TMVR devices
US$75 MILLION AGREEMENT 12/02/16}}}}

Neovasc and Boston Scientific Reach US$75 Million Agreement 
12/2/2016 7:00:00 AM - PR Newswire 

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 
12/2/2016 7:00:00 AM - PR Newswire 

NVCN + BSX = 15% stake = +350% for stock


Fred Colen - President and CEO

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.  

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member." 

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry. 

Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018
, perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.
source: https://www.massdevice.com/boston-scientific-lays-off-nearly-300-from-valencia-neuromod-facilities/ 


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 




                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"


Concensus Recommendation courtesy of NASDAQ.com 
Updated: April 1st, 2018:   STRONG BUY.
Source: https://www.nasdaq.com/symbol/nvcn/analyst-research

STRONG BUY                                  
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN News: Report of Foreign Issuer (6-k) 09:03 AM
NVCN News: Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations in Germany 09:00 AM
NVCN News: Report of Foreign Issuer (6-k) 01/21/2020 09:02:51 AM
NVCN News: Updates on Reducer and Tiara Programs Will be Presented at Advanced Cardiovascular Intervention 2020 Meeting 01/21/2020 09:00:10 AM
NVCN News: Report of Foreign Issuer (6-k) 01/15/2020 10:10:05 AM
News News Alert: Report of Foreign Issuer (6-k) 01/22/2020 09:03:15 AM
#11758   3 days of MC compliance, 7 to go. swing4thefences 01/22/20 09:58:20 AM
#11757   http://archive.fast-edgar.com//20200122/AO2Z922CZ225M2Z2222L2MO5AOHGZZ222F22/ Spikedog 01/22/20 09:25:13 AM
#11756   Shorts will burn soon imo logsplitter 01/21/20 08:19:53 AM
#11755   After hours someone bought around $4.25. Bought @ Crapola2theleft 01/15/20 12:14:59 PM
#11754   Just got 3,20,s and low 3,30,s europtiger 01/15/20 09:33:46 AM
#11753   :-) Nitwit 01/15/20 08:34:52 AM
#11752   If there is one SCD13 published tomorrow or Never_Post 01/14/20 08:27:12 AM
#11751   Wondering how much $10,000,000 worth NVCN could be Crapola2theleft 01/13/20 08:23:15 PM
#11750   Long time ago worked for one of the Never_Post 01/13/20 03:08:06 PM
#11749   Never... Oh, I'm counting on a bidding war. Crapola2theleft 01/13/20 01:52:58 PM
#11748   Hope you are right. Never_Post 01/13/20 01:21:51 PM
#11747   Never... You gave me a little more info. Crapola2theleft 01/13/20 12:48:00 PM
#11746   Additionally ... Never_Post 01/13/20 11:16:51 AM
#11745   SC13DA defined - Never_Post 01/13/20 10:43:27 AM
#11744   Never...Further speculation is that if they are listed Crapola2theleft 01/12/20 02:40:59 PM
#11743   Never... OK, you seem to know more than Crapola2theleft 01/12/20 02:01:36 PM
#11742   Thanks for posting!...good information. LutherTiggs 01/12/20 10:41:17 AM
#11741   Just an FYI, BSX ownership is at minimal Never_Post 01/11/20 12:41:42 PM
#11740   Luther... With GOHE, bought under a penny to Crapola2theleft 01/10/20 11:44:17 PM
#11739   Well, I certainly can't say that dumping GOHE LutherTiggs 01/10/20 03:48:26 PM
#11738   Luther... Good to hear from you again. How Crapola2theleft 01/09/20 09:29:56 PM
#11737   Believe I have heard 6 mos. on average... LutherTiggs 01/09/20 08:29:39 PM
#11736   Surly someone might follow the pharms. Crapola2theleft 01/09/20 11:16:00 AM
#11735   If I hear something definitive will let you know. Never_Post 01/09/20 10:13:59 AM
#11734   Not sure of timeframe, but does appear that Never_Post 01/09/20 10:12:51 AM
#11733   S, after one places an app. with the Crapola2theleft 01/08/20 06:53:50 PM
#11732   Start investing with Acorns today! Get $5 when ne14costco 01/04/20 04:55:59 PM
#11731   I have learned the hard way in the lenny_squiggy 01/02/20 10:00:00 AM
#11730   Wish I would have been smart enough to LutherTiggs 01/02/20 08:56:12 AM
#11729   This will likely come down to whether FDA LutherTiggs 01/02/20 08:53:51 AM
#11728   Clueless management. The affect of the PMA completely fenian32 01/02/20 08:32:52 AM
#11727   So do we expect this to drop to fenian32 01/02/20 08:31:19 AM
#11726   Offering..... (NVCN NVCN.T) Neovasc Announces $10 Million Registered Direct davidsson10 01/02/20 08:19:02 AM
#11725   Amazing we got the big jump last week LutherTiggs 01/02/20 08:08:02 AM
#11724   * * $NVCN Video Chart 12-31-2019 * * ClayTrader 12/31/19 04:31:54 PM
#11723   warrants done, dumped their load DeliverySuccess 12/31/19 12:53:26 PM
#11721   Pre-market Trading: Breakfast of Champions. davidsson10 12/31/19 08:26:52 AM
#11720   Dropping as I expected. Buy @ 6 Jonas83 12/31/19 08:16:00 AM
#11719   Been following this over two years, I expect Jonas83 12/31/19 07:57:20 AM
#11718   WTF TrendTrade2016 12/31/19 07:55:33 AM
#11717   If I smoked cigars, I'd be burning one davidsson10 12/31/19 07:52:44 AM
#11716   Great news — low float. Wouldn’t be swing4thefences 12/31/19 07:40:54 AM
#11715   More fun than the Ball Drop at Times Square..... davidsson10 12/31/19 07:28:03 AM
#11714   News: $NVCN Neovasc Submits Premarket Approval Application to whytestocks 12/31/19 07:15:30 AM
#11713   Today will be a Good Day, Monday and Never_Post 12/27/19 12:46:11 PM
#11712   This pos trash canadian garbage fred colen is nicoausto 12/22/19 08:15:32 AM
#11711   Volume precedes price (eom) Never_Post 12/18/19 10:08:06 AM
#11710   Synopsis of today's price action ... Never_Post 12/11/19 04:49:12 PM
#11709   FYI - Catalysts... Never_Post 11/22/19 11:17:06 AM
#11708   Well below the 4.50 offering which I would propert 11/20/19 02:44:41 PM